RESULT
The Expression pattern of PD-1 on NK, NKT, and T cells in non-M3 relapsed AML
Autologous NK cell therapy is accessible for cancer immunotherapy. However, the main question is whether these NK cells have enough ability to overcome cancer cells. Therefore, we evaluated the expression pattern of PD-1 as an inhibitor marker on NK cells in MNC derived from whole blood samples of seven patients with AML who treated by Fludarabine and Busulfan. Immunophenotyping of whole blood of patients determined that 63.25 ± 5.3% of total lymphocytes were T cells, of which 15.93±2.76% were PD-1 positive. Instead, NK (CD56+/16+CD3) cells were about 12.3±4.18% of total lymphocytes with 7.05 ± 1.14% expression of PD-1, and NKT (CD56+/16+CD3+) cells were 6.02±2.68% of total lymphocyte with 11.47± 3.28% PD-1 expressing cell (Fig. 1 ).